During Plasmodium falciparum infections, erythrocyte-stage parasites inhibit dendritic cell maturation and function, compromising effective antimalarial adaptive immunity. Human Vγ9Vδ2 T cells can act in vitro as antigen-presenting cells (APCs) and induce αβ T-cell activation. However, the relevance of this activity in vivo has remained elusive. Because Vγ9Vδ2 T cells are activated during the early immune response against P. falciparum infection, we investigated whether they could contribute to the instruction of adaptive immune responses toward malaria parasites. In P. falciparum-infected patients, Vγ9Vδ2 T cells presented increased surface expression of APC-associated markers HLA-DR and CD86. In response to infected red blood cells in vitro, Vγ9Vδ2 T cells upregulated surface expression of HLA-DR, HLA-ABC, CD40, CD80, CD83, and CD86, induced naive αβ T-cell responses, and crosspresented soluble prototypical protein to antigen-specific CD8 + T cells. Our findings qualify Vγ9Vδ2 T cells as alternative APCs, which could be harnessed for therapeutic interventions and vaccine design.
Accumulating evidence has shown that a nonconventional T cell, the γδ T cell, is involved in the early immune response to erythrocyte-stage infection of Plasmodium spp. malaria parasites, including Plasmodium falciparum and Plasmodium vivax. A subset unique to primates and expressing the Vγ9Vδ2 T-cell receptor is activated in a major histocompatibility complex (MHC)-independent manner by small nonpeptidic phosphorylated molecules commonly referred to as phosphoantigens. The most potent phosphoantigen is 4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), produced by the nonmevalonate isoprenoid pathway used by numerous microorganisms, including Apicomplexan parasites such as Plasmodium spp. (reviewed in [1] ). In vivo, human blood Vγ9Vδ2 T cells are activated and expand during primary P. falciparum infection [2, 3] . In vitro, it has been shown that Vγ9Vδ2 T cells inhibit erythrocyte-stage proliferation [4] by granulysin release targeting the extracellular invasive parasite form (merozoites) [2, 3] . Granulysin levels are elevated in malaria patients and correlate with the percentage of CD3-positive T cells expressing Vδ2 [2] , consistent with substantial degranulation of Vγ9Vδ2 T cells during P. falciparum infection.
In addition to a cytotoxic role, it has been proposed that Vγ9Vδ2 T cells can mimic in part dendritic cell (DC) function and license primary αβ T-cell responses. Vγ9Vδ2 T cells stimulated in vitro by synthetic phosphoantigens express antigen-presenting cell (APC) phenotype and display a DC-like morphology. They are able to present both viral and bacterial antigens to CD4 + αβ T cells and can even cross-present antigens to CD8 + αβ T cells [5] [6] [7] [8] [9] [10] . However, their APC potential in response to an infectious agent in vivo has yet to be demonstrated. It is possible that Vγ9Vδ2 T cells represent an alternative route of antigen presentation during the immune response that follows P. falciparum infection. This question is particularly relevant because there is both in vitro and ex vivo evidence that Plasmodium erythrocyte-stage parasites inhibit effective DC maturation and function [11] [12] [13] [14] [15] .
We therefore investigated the antigen-presenting ability of Vγ9Vδ2 T cells after exposure to erythrocyte-stage P. falciparum parasites (infected red blood cells [iRBCs] ), looking at both their phenotype and function. We found that in vivo there is an increase in surface expression of APC-associated markers on blood Vγ9Vδ2 T cells from P. falciparum-infected patients. In vitro, Vγ9Vδ2 T cells upregulated surface expression of a range of APC markers in response to iRBCs and exhibited functions of professional APCs in mixed lymphocyte reactions and a cross-presentation assay. To our knowledge, this is the first demonstration of APC activity of Vγ9Vδ2 T cells in an infectious context and has implications for therapeutic interventions and improved vaccine design.
MATERIALS AND METHODS

Clinical Samples
Clinical blood samples were collected from P. falciparuminfected patients admitted to the University Hospital of Bordeaux on admission before treatment (day 0) and, for those who came back for a medical follow-up, 7 days after treatment (day 7). Nonmalaria febrile control samples were collected as were malaria samples from patients presenting with high-grade fever and a record of travel to malaria-endemic zones but for whom malaria attack was excluded. Healthy donors from the blood bank (Etablissement Français du Sang, EFS-Aquitaine) were processed as healthy control subjects. Malaria patients were classified as described previously [16, 17] . Severe malaria was defined as described [18] . All patients gave informed consent. The ethical agreement obtained for this study was restricted to leftovers from the blood samples used for diagnosis, corresponding to approximately 0.5-1.0 mL of blood.
Antigen-Presenting Cell Phenotyping by Flow Cytometry
For ex vivo analysis, 300 µL of whole blood was labeled with anti-CD3-BV510, CD45RA-PECF5940, CD27-Alexafluor 700 (all from BD Biosciences); anti-Vδ2-PC7, CD80-FITC, CD86-phycoerythrin (PE) monoclonal antibodies (mAbs; all from Beckman Coulter); and anti-CD40-APC mAb (MiltenyiBiotech). For in vitro analysis, cells were labeled with anti-CD3-BV510, HLA-DR-Alexafluor 700, HLA-ABC-V450 mAbs (all from BD Biosciences); anti-Vδ2-FITC, CD80-PC7, CD83-PE, CD86-APC Alexafluor 750 mAbs (all from Beckman Coulter); and anti-CD40-APC mAbs (Miltenyi-Biotech). Flow cytometry data were acquired using an LSR Fortessa 2 Blue 6 Violet 3 Red 5 Yelgr laser configuration, a CantoII 4 Blue 2 Violet 2 Red laser configuration, and a Canto 4 Blue 2 Red laser configuration (all BD Biosciences). Analysis was performed using Diva 8 (BD Biosciences) and FlowJo 9.3.2 (Tristar) softwares. Total lymphocyte counts from patient blood samples were carried out by the immunology laboratory (Bordeaux University Hospital) using FC500 Beckman Coulter flow cytometers.
Parasite Culture FCR3 P. falciparum parasites were cultured in type O + red blood cells (RBCs; EFS-Aquitaine), in Roswell Park Memorial Institute 1640 medium supplemented with 10% human serum, gentamicin, glutamine, and hypoxanthine, as previously described [2, 19] . Infected red blood cell cultures were regularly tested for absence of Mycoplasma contamination. Parasitemia was assessed using hydroethidine staining, as described previously [20] , or examination of Giemsa-stained smears. Parasite cultures were synchronized by sorbitol and/or heparin treatment as described previously [21, 22] . Midstage to late schizonts approximately 36 hours after infection were purified by gel floatation on gelofusin [20] . Parasitemia after purification was >80%. Supernatant was produced as previously described [21] . For alkaline phosphatase treatment, supernatants were treated with 0.015 U/μL of shrimp alkaline phosphatase for 30 minutes at 37°C, as described previously [23] .
In Vitro Stimulation of Vγ9Vδ2 T Cells
Peripheral blood mononuclear cells (PBMCs) from malarianaive healthy donors (EFS-Aquitaine) were isolated from blood by Ficoll density gradient and cultured in complete medium (Roswell Park Memorial Institute 1640, supplemented with glutamine, antibiotics, nonessential amino acids, sodium pyruvate [all from Gibco Life Technologies], and 10% heat-inactivated fetal calf serum [PAA Laboratories]) supplemented with 100 IU/ mL of interleukin 2 (IL-2; Peprotech) in 24-well plates (Thermo Scientific). Peripheral blood mononuclear cells (1.5 × 10 6 cells/ mL) were stimulated with 5 × 10 6 iRBC/mL or 10 nM HMBPP (Echelon Biosciences). Uninfected RBCs (uiRBCs; 5 × 10 6 per milliliter) or complete medium alone were used as respective negative controls for phenotyping assays. After 72 hours of culture, 100 IU/mL of IL-2 and 25 ng/mL of interleukin 15 (IL-15; Peprotech) were added. After 12 days in culture, Vγ9Vδ2 T-cell purity was assessed by flow cytometry. If total Vδ2 + T-cell purity was <90%, cells were sorted as described below.
Mixed Lymphocyte Reaction
Monocytes from malaria-naive healthy donors' PBMCs were depleted using CD14 beads (Miltenyi-Biotech). The CD14-negative fraction was then labeled with either anti-Vδ2-FITC or anti-Vγ9-PC5 antibody (Beckman Coulter) and anti-FITC or anti-PE beads (Miltenyi-Biotech). Labeled cells were filtrated through LS then MS columns (Miltenyi-Biotech) and used when purity was >95%. Freshly sorted Vγ9 + T cells (10 5 ) were cultured with 10 4 autologous irradiated (50 Gy) monocytes as feeders and stimulated with either 10 5 -2x10 5 iRBCs, 0.2-1 nM HMBPP, or 50% volume/volume iRBC supernatant in complete medium supplemented with 100 IU/mL of IL-2. After 6 days, Vδ2 purity and phenotype were checked, and the cells were used as effectors in a mixed lymphocyte reaction (MLR). Total allogenic CD4 + and CD8 + T cells were sorted based on expression of CD4/CD8. Naive CD4 + and CD8 + T cells were sorted as CD45RA + and CCR7 + to purities of >99.2% from PBMCs of healthy donors. Sorted cells were labeled with 5 µM of carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen) in phosphate-buffered saline-5% fetal calf serum (FCS) for 5 minutes, washed thoroughly, and starved for 1 hour in complete medium at 37°C before being used as responder cells in an MLR. CD4 + and CD8 + cells (2 × 10 5 ) were mixed with decreasing ratios of irradiated (12 Gy) Vγ9 + T cells cells-namely, −1:10, 10:1, 100:1, 1000:1−in 96-well, round-bottom plates. CD4/CD8 T cells alone were incubated with 4 µg/mL of Staphylococcus Enterotoxin B (SigmaAldrich) and 40 IU/mL of IL-2 or in complete medium alone. After 5 days, cells were labeled with DAPI, anti-CD3-BV510, anti-CD4-PC7, and anti-CD8-APC mAbs. The percentages of CFSE low CD4 + and CD8 + T-cells were assessed by flow cytometry. For measurement of intracellular cytokine expression, MLR cultures were stimulated with phorbol 12-myristate 13-acetate (PMA)/ionomycin (10 ng/mL and 1 µM, respectively; both from Sigma). Brefeldin A (10 µg/mL; BioLegend) was added 1 hour later. After 5 hours of stimulation, cells were processed for extracellular and intracellular staining using the eBioscience Fix/ Perm Kit. Cultures were stained with anti-CD4-APC H7, CD8-PCy7, CD3-FITC, Vγ9-PCy5, and IFNγ-BV421 mAbs.
M1 Antigen Presentation Assay
CD8 T cells specific for M1p58-66 presented in an HLA-A2 background were generated using the influenza matrix M1 protein-derived M1p58-66 peptide (GILGFVFTL) as described previously [6, 24] . HLA-A2 + or HLA-A2 − in vitrostimulated Vγ9Vδ2 T cells (3 × 10 5 ) were incubated overnight with 0.01-1 µM M1 protein in a 96-well, round-bottom plate (Falcon) for loading. M1p58-66 (0.01 µM) was identically loaded for 1 hour immediately before coculture. Effector cells were washed and cocultured with M1p58-66-specific CD8 T-cell responders (0.3 × 10 6 ) for 4.5 hours in complete medium plus 1 µg/mL of brefeldin A. PMA/ionomycin were used as the positive polyclonal control for CD8 T-cell activation. Cells were labelled with anti-CD3-APC, CD8-PC7 mAbs (both from BD Biosciences), and anti-Vδ2-FITC mAb (Beckman Coulter), fixed with FACs lysis buffer, and permeabilized using Perm2 (both from BD Biosciences), then labelled with anti-IFNγ-PE mAb (BD Biosciences).
Statistical Analysis
Statistical analysis was performed using Graph-Pad Prism as follows: nonparametric Mann-Whitney U test for comparisons of unpaired populations; Wilcoxon signed rank test for pairwise day 0 versus day 7 comparisons; Friedman test with Dunn's multicomparison adjustment for pairwise comparisons; 2-way analysis of variance test with Bonferroni correction for timecourse comparisons. Differences were considered significant at P < .05.
RESULTS
Increased Expression of Antigen-Presenting Cell Markers in
Vγ9Vδ2 T Cells in Plasmodium falciparum Malaria Patients Compared With Healthy and Nonmalaria Febrile Control
Subjects
We first compared the surface expression of APC-marker Vγ9Vδ2 T cells in blood obtained from P.falciparuminfected adult patients, healthy control subjects, and patients presenting with fever for reasons other than malaria (Figure 1 ; Supplementary Figure 1) . Overall, we observed higher levels of HLA-DR and CD86 expression on Vδ2 + T cells from malaria patients at admission compared with healthy and nonmalaria febrile control subjects. Both nonmalaria febrile control subjects and malaria patients had a decreased CD40 expression on day 0 compared with healthy control subjects, although this was less pronounced in malaria patients. There were no significant differences in percentage of Vδ2 + /CD3 + T cells between the 3 groups ( Figure 1A) , and no CD80 expression was observed. With regard to memory phenotype, malaria patients presented less T naive and more T emra Vδ2 + T cells compared with both healthy and nonmalaria febrile control subjects ( Figure 1B) . Interestingly, there was strong homogeneity among the febrile control subjects free of malaria infection, despite presenting with heterogeneous infectious events ( Table 1) . Despite limited statistical power due to the low number of patients for whom both day 0 and day 7 blood samples were available, there appears to be a trend for an increase in percentage of Vδ2 T cells (as previously documented) and a decrease in HLA-DR and CD86 expression, although not significant ( Figure 1C ), concomitant with parasite clearance. There was also an increase in the T cm and a decrease in the T emra Vδ2 + T-cell subsets ( Figure 1C) .
To assess the effect of different previous exposures to malaria, we stratified the malaria patients between those of sub-Saharan African origin who were migrants to France and visiting friends and relatives in their country of origin (VFR), Caucasian travelers of European origin (TEO), and Caucasian travelers of European origin with a history of frequent travel to endemic regions (FTEO). The majority of the cohort patients were VFR (n = 22) ( Table 1) . Although there were no significant differences in APC or memory phenotype between the groups, the VFR group was the only group consistently significantly different from the healthy and febrile control subjects (Supplementary Figure 1B) . There was no correlation between parasitemia and APC phenotype. However, our cohort contained 1 highly severe case with 19% RBC parasitemia upon admission (Table 1 , patient 11), who showed high expression of HLA-DR and CD86 on Vδ2 + T cells and a predominant T em phenotype, which all diminished postparasite clearance ( Figure 1C and 1D) . Altogether, these data demonstrate that Vγ9Vδ2 T cells presenting phenotypic features of APCs can be found in vivo in the blood of malaria patients.
Acquisition of Antigen-Presenting Cell-likePhenotype by
Vγ9Vδ2 T Lymphocytes After In Vitro Stimulation by BloodStage Plasmodium falciparum Parasites
To investigate whether P. falciparum can induce APC maturation of Vγ9Vδ2 T cells, PBMCs from malaria-naive, afebrile healthy donors were stimulated with intact 5 × 10 6 iRBC/mL. The synthetic phosphoantigen HMBPP was used as a positive control, and 5 × 10 6 uiRBC/mL and complete medium Figure 1 . Vγ9Vδ2 T lymphocytes from Plasmodium falciparum malaria patients show increased expression of presenting and costimulatory molecules compared with healthy and nonmalaria febrile infected control subjects. Vγ9Vδ2 T lymphocytes from P. falciparum-infected patients collected at admission pretreatment were assessed for both antigen-presenting cell (APC) and memory phenotypes. Patients with nonmalaria febrile symptoms and non-malaria-exposed healthy donors were used as control subjects. Percentage of HLA-DR, CD40, and CD86 + /Vδ2 + T cells (A) and T naive , T cm , T em , and T emra Vδ2 + T cells (B) in whole blood from healthy control subjects (n = 11), febrile control subjects (n = 6), and malaria patients at the time of hospital admission (n = 27). Each point represents an individual patient. The mean is indicated by the horizontal bar. Data were analysed using Mann-Whitney U test for unpaired samples (**P < .01, *P < .05). C, Percentage of HLA-DR, CD40, and CD86 + /Vδ2 + T cells (left panel) and percentage of T naive , T cm , T em , and T emra Vδ2 + T cells (right panel) in the 5 patients from whom paired blood samples on the day of admission (D0) and on day 7 after treatment (D7) were obtained. The trends observed were nonsignificant as calculated by a Wilcoxon signed rank test for matched pairs. D, Histograms (unstained control in gray) at D0 and percentage of APC and memory phenotype of Vδ2 + T cells on D0 and D7 in whole blood of a severe malaria case (patient no. 11) presenting with 19% parasitemia at admission. were used as negative controls (Figure 2 ). We found that iRBC stimulation significantly increased expression of all APC-associated markers tested over a 12-day culture period, although with different kinetics (Figure 2A ; Supplementary  Figure 2 ). Infected RBCs induced a lower magnitude of expression than HMBPP. Expression of all APC markers was induced in the negative controls, but to lower/marginal levels and with delayed kinetics. This was likely due to the presence of IL-2 and IL-15 in the culture medium, indicating that APClike phenotype acquisition is not solely dependent on T-cell receptor signaling. These results indicate that P. falciparum can promote the expression of an APC phenotype by Vγ9Vδ2 T cells in vitro.
Antigen-Presenting Cell-like Functions of Vγ9Vδ2 T Lymphocytes After In Vitro Stimulation by Blood-Stage
Plasmodium falciparum Parasites
One of the hallmarks of APCs is the ability to stimulate allogenic αβ T cells. We thus tested the capacity of peripheral bloodisolated Vγ9Vδ2 T cells stimulated in vitro with P. falciparum to activate CD4 + and CD8 + αβ T cells in an MLR. Vγ9Vδ2 T cells stimulated by intact iRBCs induced proliferation of total allogenic CD4 + and CD8 + T cells ( Figure 3A) . Moreover, Vγ9Vδ2 T cells stimulated with iRBC culture supernatant induced both proliferation ( Figure 3B ) and cytokine production ( Figure 3C ) by allogenic-naive CD4 + and CD8 + T cells, demonstrating genuine professional APC activity. Indeed, naive αβ T-cell activation was not observed with unstimulated Vγ9Vδ2 T cells ( Figure 3B ). Much lower activity was observed when using the uiRBC culture supernatant and alkaline phosphatase-treated iRBC culture supernatant. This is in agreement with the susceptibility of parasite-derived phosphoantigens to dephosphorylation and rules out the requirement of unrelated parasite or RBC molecules for the induction of APC features in Vγ9Vδ2 T cells.
It has been documented that isopentenylpyrophosphate-or HMBPP-stimulated Vγ9Vδ2 T cells can efficiently cross-present exogenous antigens to CD8 + T cells [6, 24] . To assess whether P. falciparum-stimulated Vγ9Vδ2 T cells have the same ability, we used an antigen presentation assay based upon the processing and presentation of the influenza virus M1 antigen to M1p58-66-specific CD8 + T cells in an HLA-A2 background (Figure 4) . We found that P. falciparum-stimulated, M1 protein-loaded Vγ9Vδ2 T cells activated the M1p58-66-specific CD8 + T-cell responder line as efficiently as HMBPP-stimulated Vγ9Vδ2 T cells ( Figure 4B ). This activation was dependent on both M1 protein loading and HLA-A2 expression by the Vγ9Vδ2 T cells, demonstrating that activation was due to M1 protein uptake, processing, and cross-presentation of the M1p58-66 epitope.
Taken together, our results show that P. falciparumstimulated Vγ9Vδ2 T cells readily acquire the potential to act as professional APCs and induce responses by CD4 + and CD8 + T cells. b Insufficient (<200) Vγ9Vδ2 T-cell events recorded. Therefore patient was not included in Figure 1 analysis. 
DISCUSSION
Protective immunity to malaria infection in endemic areas is acquired slowly over many years of exposure and is not stable. There are many explanations for this, including P. falciparum antigenic diversity, T-cell inhibition, and B-cell modulation in infected individuals (reviewed in [25] ). In addition, parasites have evolved mechanisms to inhibit the antigen-presenting machinery. There is both in vitro and ex vivo evidence that iRBCs inhibit effective DC maturation and function [11] [12] [13] [14] [15] .
Our results indicate that Vγ9Vδ2 T cells, which are efficiently activated in vivo during P. falciparum infection, could thus represent an alternative route for antigen presentation to αβ T cells in the context of malaria. We show that in vivo-stimulated Vγ9Vδ2 T cells from malaria patients display a membrane phenotype associated with conventional APCs, which is not observed in the febrile nonmalaria-infected control subjects. The size increase and stability of the peripheral blood memory subpopulations indicate that, although the patients were lymphopenic, malaria did not damage the blood central memory compartment as reported for HIV infections [26] . From our malaria patient subgrouping, it appears that originating from a malaria-endemic area correlates with a higher ex vivo Vγ9Vδ2 T-cell APC phenotype upon infection. Previous studies have shown that Vδ1 + , not Vδ2 + , T cells are expanded in the peripheral blood of malaria patients from endemic regions [27] . Our data may possibly reflect a situation where Vδ2 + T cells take on an APC phenotype once their inflammatory functions are downregulated. Vγ9Vδ2 T cells express the chemokine CCR7 after phosphoantigen stimulation in vitro [28] ; thus their absence from peripheral blood could be due to their migration to lymphoid organs. However, because the sample size of the TEO and FTEO groups was small (n = 4 in each group), this interpretation needs to be further substantiated. Further, we cannot rule out a genetic effect in patients of different ethnic backgrounds in the VFR and TEO/FTEO groups. Systematic information on previous malaria infection(s), the duration of residence of VFR in both their native country and France, and the frequency of visits to endemic regions in the VFR and FTEO groups were not available. In this study, we focused on samples taken before treatment, resulting in mainly recruiting nonsevere and mildly severe malaria cases. This may have led to underestimating the average level of Vγ9Vδ2 T cells displaying an APC phenotype in malaria patients, given that the strongest APC phenotype was seen in our unique extremely severe malaria patient. From this severe hyperparasitemic case, it is clear that high HLA-DR and CD86 expression can occur in Vγ9Vδ2 T cells during acute malarial infection. The dramatic decrease of both HLA-DR and CD86 expression by day 7, after patient recovery, further indicates that this APC-like phenotype was transient in blood and associated with acute infection. In A, global analysis was performed excluding SEB condition used as positive control for αβ T-cell proliferation (***P < .001, **P < .01, *P < .05). Abbreviations: AP, alkaline phosphatase; CFSE, carboxyfluorescein succinimidyl ester; HMBPP, 4-hydroxy-3-methyl-but-2-enyl diphosphate; IFNγ, interferon γ; iRBC, infected red blood cell; ns, nonstimulated; SEB, Staphylococcus Enterotoxine B; SN, supernatant; uiRBC, uninfected RBC; unstim, unstimulated Vγ9Vδ2 T cells.
Little in vivo evidence of APC-like phenotype and functions of γδ T cells have been documented. In mice, where a Vγ9Vδ2 T-cell equivalent population has yet to be found, Frossard et al described the APC-like phenotype of γδ T cells induced in vivo by cholera toxin and their role in the modulation of oral tolerance in food allergy pathogenesis [29] . More recently, Wan et al described γδ T cells with APC-like capabilities in zebrafish [30] . This work presents the first evidence to our knowledge of Vγ9Vδ2 T-cell APC-like differentiation occurring physiologically in humans in a pathological situation.
The presence of Vγ9Vδ2 T cells with an APC-like phenotype in malaria patients is supported by our demonstration that in vitro iRBC-stimulated Vγ9Vδ2 T cells readily express both presenting and costimulatory molecules associated with APCs. As a confirmation of the functional relevance of these findings, we showed that iRBC-stimulated Vγ9Vδ2 T cells can take up, process, and cross-present exogenous M1 protein to M1p58-66-specific CD8 T cells as effectively as in vitro HMBPP-stimulated Vγ9Vδ2 T cells. Plasmodium falciparum-stimulated Vγ9Vδ2 T cells were also capable of activating naive allogenic αβ T cells, as shown by our MLR experiments. In this model, we observed some activation of αβ T cells by Vγ9Vδ2 T cells cultured with uiRBC supernatant, consistent with the induction of a small proportion of APC Vγ9Vδ2 T cells in this condition ( Figure  2) , which is probably due to the presence of IL-2 and IL-15 in the culture medium. HMBPP stimulation consistently induced increased expansion and APC-marker expression in Vγ9Vδ2 T cells compared with iRBC stimulation. This could be due to lower phosphoantigen levels with iRBC stimulation (5 × 10 6 iRBC/mL equates to approximately 1 nM HMBPP [31] ), but we cannot rule out the presence of some iRBC-derived inhibitor mitigating the activation. Infected RBC-released molecules such as hemozoin have been shown to inhibit DC maturation [13] . However, if similar inhibition occurs for the Vγ9Vδ2 T cells, it does not overtake their activation by phosphoantigens. CD36-dependent iRBC adhesion has also been proposed to mediate DC inhibition [15] . The FCR3 parasite strain used in our assays was nonadherent; therefore CD36-mediated inhibition would not occur in our experimental system. Because CD36 expression of Vγ9Vδ2 T cells after zoledronate stimulation has been documented [32] , it will be important to assess Vγ9Vδ2 T-cell APC-like maturation after coculture with CD36-binding iRBCs. Recent data on Mycobacteria immunity [33] showed that APC functions of Vγ9Vδ2 T cells do not require soluble mediators and involve cell-to-cell contact. In our study, both intact iRBCs and soluble products from P. falciparum were able to stimulate Vγ9Vδ2 T cells. Moreover, the abrogation of such stimulation after phosphatase treatment of the supernatants indicates that soluble phosphorylated mediators are necessary to induce APC-like functions. Thus, it is likely M. tuberculosis and P. falciparum differ in their mechanisms of APC induction in Vγ9Vδ2 T cells.
Magnitudes and kinetics of APC-marker stimulation differ [29, 30, 32, 33] , suggesting that in vitro culture conditions can modulate Vγ9Vδ2 T-cell APC maturation kinetics. Under the stimulatory conditions we used, there appears to be 2 patterns of expression, at least within the timeframe of our observation, with first transient expression of CD40 and CD83 alongside increased HLA class I expression and later on stable expression of HLA-DR, alongside expression of CD80 and CD86. Although peak expression points did not coincide for the 2 types of phenotype, expression of all markers was above baseline between day 6 and day 9, when Vγ9Vδ2 T cells were stimulated among the PBMCs, and between day 3 and day 6, when they were purified before stimulation. In the latter situation, the pattern was sufficient to induce allogenic αβ T-cell stimulation. From our kinetics data, one can surmise that in vivo the Vγ9Vδ2 T-cell APCs have matured sufficiently after 3-5 days of iRBC exposure. Based on their parasitemia at admission, the patients have experienced on average 3-5 replication cycles (ie, approximately 6-10 days of blood-stage infection). Thus, the reduced CD40 and high HLA-DR and CD86 levels in patients' Vγ9Vδ2 T cells correlate with the kinetics of expression observed in our cultured lines. It will be important to assess the functional ability of in vivo iRBC-induced Vγ9Vδ2 T-cell APC-like cells. Our study design did not allow investigating this point, which requires the collection of much larger volumes of blood from patients.
Taken together, our study proposes a novel role for human Vγ9Vδ2 T cells in malaria-infected patients, promoting initiation of the adaptive response despite a possible impairment of conventional APCs.
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